Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biocytogen Pharmaceuticals has announced that IDEAYA Biosciences has exercised an exclusive worldwide license for Biocytogen’s bispecific antibody-drug conjugate, IDE034. This move could bring Biocytogen up to $406.5 million in various payments, as IDEAYA plans to advance IDE034 towards an IND submission to the FDA by 2025.
For further insights into HK:2315 stock, check out TipRanks’ Stock Analysis page.